## PaweÅ, Andrzej PtaszyÅ, "ski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/519029/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal, 2016, 37, 2882-2889.	2.2	222
2	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2017, 103, 307-314.	2.9	205
3	Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension. JAMA - Journal of the American Medical Association, 2020, 323, 248.	7.4	134
4	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation, 2021, 143, 7-17.	1.6	132
5	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	2.5	118
6	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	1.9	92
7	Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace, 2013, 15, 116-121.	1.7	85
8	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE, 2018, 13, e0191592.	2.5	80
9	Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. European Heart Journal, 2020, 41, 3437-3447.	2.2	78
10	Quantitative Assessment of Microvolt T-Wave Alternans in Patients with Congestive Heart Failure. Journal of Cardiovascular Electrophysiology, 2005, 16, 620-624.	1.7	72
11	Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. Lancet, The, 2019, 394, 1344-1351.	13.7	49
12	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	2.7	45
13	Management and 1‥ear Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
14	lvabradine in Combination With Metoprolol Succinate in the Treatment of Inappropriate Sinus Tachycardia. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 338-344.	2.0	43
15	Inflammation and arrhythmias: potential mechanisms and clinical implications. Expert Review of Cardiovascular Therapy, 2014, 12, 1077-1085.	1.5	30
16	Impact of gender on event rates at 1â€year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open, 2017, 7, e014579.	1.9	30
17	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal, 2018, 39, 464-473.	2.2	28
18	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA Cardiology, 2019, 4, 526.	6.1	26

#	Article	IF	CITATIONS
19	Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. Europace, 2020, 22, 162-169.	1.7	26
20	Bedside risk stratification after acute myocardial infarction: Prospective evaluation of the use of heart rate and left ventricular function. Journal of Electrocardiology, 2005, 38, 106-112.	0.9	25
21	Heart rate turbulence and other autonomic risk markers for arrhythmia risk stratification in dilated cardiomyopathy. Journal of Electrocardiology, 2008, 41, 306-311.	0.9	25
22	Ivabradine in the Treatment of Inappropriate Sinus Tachycardia in Patients after Successful Radiofrequency Catheter Ablation of Atrioventricular Node Slow Pathway. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 42-49.	1.2	19
23	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
24	Stroke prevention in patients from Latin American countries with nonâ€valvular atrial fibrillation: Insights from the GARFIELDâ€AF registry. Clinical Cardiology, 2019, 42, 553-560.	1.8	16
25	Noninvasive Assessment of Autonomic Cardiovascular Activity in Patients With Inappropriate Sinus Tachycardia. American Journal of Cardiology, 2013, 112, 811-815.	1.6	14
26	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
27	Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators. Diabetes Care, 2020, 43, 196-200.	8.6	11
28	Cryoablation for treatment of cardiac arrhythmias: results of the European Heart Rhythm Association survey. Europace, 2017, 19, 303-307.	1.7	7
29	Clinical significance of microvolt T-wave alternans. Herzschrittmachertherapie Und Elektrophysiologie, 2007, 18, 39-44.	0.8	6
30	The clinical value of T-wave alternans derived from Holter monitoring. Europace, 2017, 19, euw292.	1.7	6
31	Percutaneous Occlusion of the Left Atrial Appendage with Thrombus Irresponsive to Antithrombotic Therapy. Journal of Clinical Medicine, 2021, 10, 726.	2.4	6
32	Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug, Healthcare and Patient Safety, 2014, 6, 47.	2.5	5
33	Atypical position of subcutaneus implantable cardioverter-defibrillator as a solution in hypertrophic cardiomyopathy patient with initially negative electrocardiographic screening:. European Heart Journal, 2015, 36, 2542-2542.	2.2	5
34	Baseline intrinsic heart rate and response to ivabradine treatment in patients with inappropriate sinus tachycardia. Annals of Noninvasive Electrocardiology, 2020, 25, e12709.	1.1	4
35	Relationship Between Changes in Pulse Pressure and Frequency Domain Components of Heart Rate Variability During Short-Term Left Ventricular Pacing in Patients with Cardiac Resynchronization Therapy. Medical Science Monitor, 2016, 22, 2043-2049.	1.1	4
36	Potential benefit of optimizing atrioventricular & interventricular delays in patients with cardiac resynchronization therapy. Indian Journal of Medical Research, 2017, 146, 71.	1.0	4

## PaweÅ, Andrzej PtaszyÅ, "ski

#	Article	IF	CITATIONS
37	A subcutaneous implantable cardioverter-defibrillator — the first implantation in Poland. Kardiologia Polska, 2015, 73, 62-62.	0.6	4
38	Risk stratification after myocardial infarction: a new method of determining the neural component of the baroreflex is potentially more discriminative in distinguishing patients at high and low risk for arrhythmias. Europace, 2008, 10, 227-234.	1.7	3
39	A New Type of Dual Atrioventricular Nodal Nonreentrant Tachycardia. Annals of Noninvasive Electrocardiology, 2014, 19, 501-503.	1.1	3
40	Multicentre early experience with totally subcutaneous cardioverter-defibrillators in Poland. Archives of Medical Science, 2020, 16, 764-771.	0.9	3
41	Safety of cryoballoon ablation for the treatment of atrial fibrillation: First European results from the cryo AF Global Registry. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 883-894.	1.2	3
42	A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI. International Journal of Cardiology, 2022, 347, 1-7.	1.7	3
43	Renal Denervation—Hypes and Hopes. Cardiovascular Therapeutics, 2015, 33, 141-144.	2.5	2
44	Self-terminating ventricular fibrillation recorded by an implantable loop recorder as a cause of syncope – A case report. Journal of Electrocardiology, 2018, 51, 617-619.	0.9	2
45	Device embolization into the LV following left atrial endage closure with an Amplatzer Amulet. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 171-172.	1.3	2
46	Combined therapy with cardiac contractility modulation and subcutaneous implantable cardioverter-defibrillator: the first experience in Poland. Kardiologia Polska, 2018, 76, 1740-1740.	0.6	2
47	A local cryotherapy with percutaneous tumour removal as a successful treatment option in patient with tricuspid valve fibroelastoma papillare. European Heart Journal, 2017, 38, ehw516.	2.2	1
48	IVABRADINE IN PATIENTS WITH SYMPTOMATIC INAPPRIOPRATE SINUS TACHYCARDIA: LONG-TERM OBSERVATIONAL STUDY. Journal of the American College of Cardiology, 2017, 69, 306.	2.8	1
49	Severe atrial fibrosis as a cause of significant intraatrial conduction delay in a patient with scleromyositis. Journal of Electrocardiology, 2019, 56, 77-80.	0.9	1
50	An electrophysiological approach using 3D electroanatomical mapping system for catheterbased renal denervation: the first Polish experience. Kardiologia Polska, 2013, 71, 990-990.	0.6	1
51	Impedance fluctuation and steam pop occurrence during radiofrequency current ablation: An experimental in vitro model. Advances in Clinical and Experimental Medicine, 2021, 30, 1051-1056.	1.4	1
52	Leadless pacemaker and subcutaneous implantable cardioverter-defibrillator therapy: the first use of a novel treatment option in Poland. Kardiologia Polska, 2018, 76, 1026-1026.	0.6	1
53	Statement by a Working Group conceived by the Polish National Consultants in Cardiology and Neurology addressing the use of implantable cardiac monitors in patients after ischaemic embolic stroke of undetermined source. Neurologia I Neurochirurgia Polska, 2019, 53, 181-189.	1.2	1
54	Noninvasive arrhythmia risk stratification?update 2003. Herzschrittmachertherapie Und Elektrophysiologie, 2003, 14, 192-198.	0.8	0

## PaweÅ, Andrzej PtaszyÅ",ski

#	Article	IF	CITATIONS
55	Interventional treatment of atrial fibrillation – contemporary methods and perspectives. Expert Review of Medical Devices, 2014, 11, 595-603.	2.8	Ο
56	Reestratificación en el momento del recambio del desfibrilador automático implantable. Revista Espanola De Cardiologia, 2014, 67, 971-973.	1.2	0
57	Restratification at Time of Implantable Cardioverter Defibrillator Replacement. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 971-973.	0.6	Ο
58	Inappropriate sinus tachycardia – clinical picture and possible psychogenic basis. Psychiatria I Psychologia Kliniczna, 2014, 14, 245-249.	0.2	0
59	Cardiac contractility modulation: a new treatment option for chronic heart failure in Poland. Kardiologia Polska, 2016, 74, 1030-1030.	0.6	0
60	Nieadekwatna tachykardia zatokowa – choroba serca czy zaburzenie związane z lękiem?. Psychiatria I Psychologia Kliniczna, 2016, 16, 126-130.	0.2	0
61	Straight and crosier‑shaped catheter techniques for phrenic nerve stimulation during cryoballoon pulmonary vein isolation for the treatment of atrial fibrillation. Kardiologia Polska, 2019, 77, 868-874.	0.6	Ο
62	New Polish prototypes of 4- and 8-mm-tip nonirrigated radiofrequency ablation catheters: an in vitro study. Kardiologia Polska, 2020, 78, 1142-1147.	0.6	0